Kenfarb & Co’s Haemonetics HAE Stock Holding History

Kenfarb & Co’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$7K	–	231
2022 Q3	$7K	Buy	+100	New	+$7.18K	0.01%	194

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Kenfarb & Co's HAE Position: Q4 2022 in Review

Kenfarb & Co sold out of Haemonetics (HAE) in Q4 2022, closing a stake of 100 shares — an estimated $7K sold.

Kenfarb & Co first reported a position in HAE in Q3 2022 and held it in 1 quarter. The position peaked at $7K in Q3 2022. 294 funds tracked by Wall St. Rank hold HAE as of Q4 2022.

Kenfarb & Co reported no remaining Haemonetics position as of Q4 2022 after selling out during the quarter.
Kenfarb & Co sold 100 Haemonetics shares in Q4 2022, an estimated $7K.
Kenfarb & Co first reported a position in Haemonetics in Q3 2022 and held it in 1 quarter.
Kenfarb & Co's Haemonetics position peaked at $7K in Q3 2022.
294 funds tracked by Wall St. Rank held Haemonetics as of Q4 2022.

Based on Kenfarb & Co's 13F filing for Q4 2022, filed 14 Feb 2023.